Novartis Phase 3 Canopy-A Trial Didn't Meet Primary Endpoint
15 Agosto 2022 - 3:05AM
Dow Jones News
By Kim Richters
Novartis AG's Phase 3 Canopy-A study for canakinumab as adjuvant
treatment in non-small cell lung cancer didn't meet the primary
endpoint of disease-free survival versus placebo.
The Swiss pharmaceutical company said Monday that it will
present findings from the study, which concerned patients with
stages II-IIIA and IIIB completely resected non-small cell lung
cancer, at an upcoming medical meeting.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
August 15, 2022 01:50 ET (05:50 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024